Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries)

International Journal of Infectious Diseases

Volumn 11, Issue SUPPL. 2, 2007, Pages

  Vesikari, Timo ^a   Itzler, Robbin ^b   Matson, David O ^c   Santosham, Mathuram ^d   Christie, Celia D C ^e   Coia, Michele ^b   Cook, John R ^b   Koch, Gary ^f   Heaton, Penny ^g  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b MERCK RESEARCH LABORATORIES   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF THE WEST INDIES   (Jamaica)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g NOVAVAX INC   (United States)

Author keywords

Emergency department; Health care utilization; Hospitalizations; Human bovine reassortant pentavalent rotavirus vaccine; Rotavirus; Vaccine

Indexed keywords

PENTAVALENT ROTAVIRUS VACCINE; PLACEBO; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

CENTRAL AMERICA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HUMAN EXPERIMENT; INFANT; INFECTION CONTROL; MALE; MULTICENTER STUDY; NORMAL HUMAN; POISSON DISTRIBUTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; ROTAVIRUS; SOUTH AMERICA; UNITED STATES; VACCINATION; VIRAL GASTROENTERITIS; VIRUS INFECTION;

COHORT STUDIES; EMERGENCY MEDICAL SERVICES; EUROPE; FEMALE; GASTROENTERITIS; HOSPITALIZATION; HUMANS; INFANT; LATIN AMERICA; MALE; REASSORTANT VIRUSES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; UNITED STATES;

EID: 37349059999     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(07)60019-8     Document Type: Review

References (18)

1. Glass R., Bresee J., Parashar U., et al. Rotavirus vaccines: past, present, and future. Arch Pediatr 12 (2005) 844-847
2. Velázquez F., Matson D., Calva J., et al. Rotavirus infection in infants as a protection against subsequent infections. N Engl J Med 335 (1996) 1022-1028
3. Vesikari T., Matson D., Dennehy P., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 (2006) 23-33
4. Vesikari T. Rotavirus vaccines against diarrhoeal disease. Lancet 350 (1997) 1538-1541
5. DiStefano D., Kraiouchkine N., Mallette L., et al. Novel rotavirus VP7 typing assay using a one-step reverse transcriptase PCR protocol and product sequencing and utility of the assay for epidemiological studies and strain characterization, including serotype subgroup analysis. J Clin Microbiol 43 (2005) 5876-5880
6. Stokes M., Davis C., and Koch G. Categorical data analysis using the SAS system (2000), SAS Institute, Inc., Cary, NC
7. Zeger S., Liang K., and Albert P. Models for longitudinal data: a generalized estimating equation approach. Biometrics 44 (1988) 1049-1060
8. Jovanovic B., and Zelenski R. Safety evaluation and confidence intervals when the number of observed events is small or zero. Ann Emerg Med 30 (1997) 301-306
9. Linhares A., Gabbay Y., Mascarenhas J., et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull World Health Organ 74 (1996) 491-500
10. Pérez-Schael I., Guntiñas M., Pérez M., et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 337 (1997) 1181-1187
11. Rennels M., Glass R., Dennehy P., et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 97 (1996) 7-13
12. Joensuu J., Koskenniemi E., Pang X., and Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 350 (1997) 1205-1209
13. Isaacman D., Kaminer K., Veligeti H., et al. Comparative practice patterns of emergency medicine physicians and pediatric emergency medicine physicians managing fever in young chilsdren. Pediatrics 108 (2001) 354-358
14. Centers for Disease Control and Prevention. Prevention of ro tavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55 No. RR-12 (2006) 1-13
15. Soriano-Gabarro M., Mrukowicz J., Vesikari T., and Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 25 1 Suppl (2006) S7-S11
16. Vesikari T., Rautanen T., and Von Bonsdorff C. Rotavirus gastroenteritis in Finland: burden of disease and epidemiological features. Acta Paediatr Suppl 88 (1999) 24-30
17. Georges-Courbot M., Monges J., Siopathis M., et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 142 (1991) 405-411
18. Hanlon P., Hanlon L., Marsh V., et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1 (1987) 1342-1345